Oncosoft (CEO Jin-sung Kim), an AI-based radiotherapy solution company, announced on the 19th that it has signed a technology transfer agreement for core technologies in the field of heavy ion radiotherapy with the University-Industry Foundation of Yonsei University Health System (YUHS).
The signing ceremony was attended by Chang-oh Kim, Director of the University-Industry Foundation of YUHS, and Jin-sung Kim, CEO of Oncosoft, with Professor Ho-jin Kim of YUHS participating as the lead investigator for the technology transfer.
According to Oncosoft, this technology transfer was achieved based on the outcomes of a joint research project under the Korea Medical Device Development Fund (KMDF) with Yonsei Cancer Hospital.
The technology acquired by the company is "Dose Optimization Technology Considering Biological Effects in Heavy Ion Radiotherapy." The goal is to enable the development of treatment plans more suitable for clinical application by considering not only physical doses but also biological characteristics when establishing heavy ion radiotherapy plans. Following a domestic patent application in March, the technology completed a PCT international application in June, and procedures for securing global intellectual property rights are currently underway.
With this acquisition, Oncosoft is evaluated to have secured high-level treatment planning technology based on biophysical simulation, moving beyond its status as an AI company specializing in radiation cancer treatment. The company stated that by expanding its portfolio into the areas of "Dose and Beam Optimization and Biological Model-based Treatment Planning"—the core of particle therapy—it is now standing shoulder-to-shoulder with global competitors.
Oncosoft plans to integrate the acquired technology into its AI-based particle radiotherapy planning software, "OncoPlan," with the aim of commercialization by 2027.
According to the Particle Therapy Co-Operative Group (PTCOG), the number of particle therapy centers worldwide is expected to increase to 250 by 2035. Oncosoft anticipates that demand for expensive Treatment Planning Systems (TPS) will rise as domestic medical institutions, including Asan Medical Center and Samcheok City, consider introducing heavy ion therapy centers, and several others, such as Seoul St. Mary's Hospital, look into proton therapy centers.
Professor Ho-jin Kim said, "Based on the heavy ion therapy experience and clinical data of Yonsei Cancer Hospital, we are verifying a platform that can compete with existing commercial software. We are also developing optimization algorithms with performance superior to commercial software and AI-based heavy ion treatment planning technology."
Jin-sung Kim, CEO of Oncosoft, stated, "This technology transfer will serve as an opportunity for us to advance as a global medical physics company. By securing next-generation treatment planning technology based on biophysics, we have established a foothold for a great leap forward." He added, "Starting with this collaboration, we will expand our business not only in Korea but also into the global market."
